Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Mocertatug rezetecan (Mo-Rez)
Mocertatug rezetecan · 6 trials · 4 indications
PFS is defined as the time from the date of randomization to the date of first documented Progressive Disease (PD) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) by Blinded independent central review (BICR) assessment or death from any cause, whichever occurs first
PFS is defined as the time from the date of randomization to the date of first documented disease progression (PD) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) by Blinded independent central review (BICR) assessment or death from any cause, whichever occurs first.
PFS is defined as the time from the date of randomization to the date of first documented Progressive Disease (PD) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) by Blinded independent central review (BICR) assessment or death from any cause, whichever occurs first
OS is defined as the time from the date of randomization to the date of death due to any cause
ORR is defined as the percentage of participants with best overall confirmed response of either complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) by Blinded independent central review (BICR)
ORR is defined as the proportion of participants with at least one confirmed Complete Response (CR) or Partial Response (PR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
| Arm | Type | Description |
|---|---|---|
| Mocertatug rezetecan +/- Bevacizumab | EXPERIMENTAL | - |
| Active Observation +/- Bevacizumab | ACTIVE_COMPARATOR | - |
| Mocertatug rezetecan (Mo-Rez) + Bevacizumab | EXPERIMENTAL | Participants will receive Mo-Rez + bevacizumab. |
| Platinum doublet + Bevacizumab | ACTIVE_COMPARATOR | Participants will receive platinum doublet chemotherapy (carboplatin with paclitaxel, gemcitabine, or pegylated liposomal doxorubicin \[PLD\]) and bevacizumab, followed by bevacizumab maintenance therapy. |
| Mocertatug rezetecan plus physician's choice of immunotherapy (dostarlimab or pembrolizumab) | EXPERIMENTAL | Participants will receive Mocertatug rezetecan along with physician's choice of immunotherapy (Dostarlimab or Pembrolizumab) |
| Physician's choice of immunotherapy (dostarlimab or pembrolizumab) | ACTIVE_COMPARATOR | Participants will receive physician's choice of immunotherapy (Dostarlimab or Pembrolizumab alone) |
| Mocertatug rezetecan | EXPERIMENTAL | Participants will receive Mocertatug rezetecan |
| Standard of care | ACTIVE_COMPARATOR | Participants will receive standard of care chemotherapy (Paclitaxel or Pembrolizumab + paclitaxel ± bevacizumab or PLD or Topotecan or Gemcitabine) as per investigator's choice |
| Part 1: Dose Escalation | EXPERIMENTAL | Participants with advanced solid tumors who are refractory or intolerant to established standard therapies |
| Part 2: Dose Expansion | EXPERIMENTAL | Participants with platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC) |
| Name | Type | Description |
|---|---|---|
| Mocertatug rezetecan | DRUG | Mocertatug rezetecan will be administered |
| Bevacizumab | DRUG | Bevacizumab will be administered |
| Mocertatug rezetecan (Mo-Rez) | DRUG | Mocertatug rezetecan will be administered |
| Carboplatin | DRUG | Carboplatin will be administered |
| Paclitaxel | DRUG | Paclitaxel will be administered |
| Gemcitabine | DRUG | Gemcitabine will be administered |
| Pegylated liposomal doxorubicin (PLD) | DRUG | PLD will be administered |
| Dostarlimab | DRUG | Dostarlimab will be administered |
| Pembrolizumab | DRUG | Pembrolizumab will be administered |
| Topotecan | DRUG | Topotecan will be administered |
| Doxorubicin | DRUG | Doxorubicin will be administered |
Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: * Is at least 18 years of age and the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Informed Consent Form (ICF). * Has new...
Mocertatug rezetecan is an investigational small molecule being studied for the treatment of ovarian cancer, endometrial cancer, and other solid tumors. It is being evaluated in Phase 3 clinical trials for platinum-resistant ovarian cancer, platinum-sensitive ovarian cancer, and endometrial cancer after prior platinum-based chemotherapy and immunotherapy.
Mocertatug rezetecan is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is sponsoring multiple Phase 3 clinical trials to investigate the drug's efficacy and safety in various oncology indications.
Mocertatug rezetecan is currently in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 3 trials are designed to compare the drug with standard of care treatments in patients with ovarian and endometrial cancers.
Mocertatug rezetecan is being studied in several Phase 3 trials, including NCT07286266 for platinum-resistant ovarian cancer, NCT07286331 for endometrial cancer, NCT07684612 for platinum-sensitive ovarian cancer, and NCT07694427 for first-line maintenance treatment of non-homologous recombination deficient ovarian cancer. These trials are actively recruiting or planned.
Yes, Mocertatug rezetecan is also known as Mo-Rez. The abbreviation Mo-Rez is used in clinical trial titles and refers to the same investigational drug. Researchers and clinicians may refer to the drug by either name in publications and trial documentation.
Mocertatug rezetecan is a small molecule being investigated for its anticancer activity. The specific molecular target has not been disclosed in the available clinical trial information. The drug is being evaluated in patients with ovarian cancer, endometrial cancer, and other solid tumors to determine its efficacy and safety.